肠道微生物组与Graves病及Graves眼病相关:INDIGO欧洲多中心研究
该多中心观察性研究纳入4个欧洲国家的105例Graves病患者和41名健康对照,比较粪便微生物组。结果发现GD/GO患者放线菌门显著增加、拟杆菌门显著减少,厚壁菌门与拟杆菌门比值显著升高;某些梭菌目细菌的存在与抗甲状腺药物治疗200天后TRAb持续相关。
要点
- GD/GO患者放线菌门显著增加、拟杆菌门显著减少,厚壁菌门与拟杆菌门比值显著高于健康对照。
- 患者中15个属的丰度存在差异,在轻度GO中偏移最明显;拟杆菌与TSH正相关、与游离甲状腺素负相关,并与GO吸烟显著相关。
- 诊断时某些梭菌目细菌的存在与抗甲状腺药物治疗开始200天后TRAb持续相关。
核心结论
- GD/GO中观察到的厚壁菌门与拟杆菌门比值升高与小鼠模型比较TSHR免疫组与对照组的结果一致。
- 研究定义了微生物组特征,并识别出与自身免疫相关的变化,这些变化区别于甲状腺功能亢进所致的变化。
- TRAb持续可预测复发;通过微生物组在诊断时识别这些患者可能改善管理,并有望根除梭菌目。
研究设计与样本
- 观察性研究,包含横断面和纵向成分,从4个欧洲国家招募105例GD患者和41名健康对照。
主要发现
- 招募时患者为甲状腺功能亢进且TRAb阳性,GD/GO与健康对照相比放线菌门显著增加、拟杆菌门显著减少。
- GD/GO的厚壁菌门与拟杆菌门比值显著高于健康对照。
- 患者中观察到15个属的差异丰度,在轻度GO中偏移最明显。
- 拟杆菌与TSH呈正相关、与游离甲状腺素呈负相关,并在GO中与吸烟显著相关;吸烟是GO而非GD的危险因素。
- 纵向分析显示,诊断时某些细菌(梭菌目)的存在与开始抗甲状腺药物治疗200多天后TRAb持续相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Gut bacteria can influence host immune responses but little is known about their role in tolerance-loss mechanisms in Graves disease (GD; hyperthyroidism caused by autoantibodies, TRAb, to the thyrotropin receptor, TSHR) and its progression to Graves orbitopathy (GO). OBJECTIVE: This work aimed to compare the fecal microbiota in GD patients, with GO of varying severity, and healthy controls (HCs). METHODS: Patients were recruited from 4 European countries (105 GD patients, 41 HCs) for an observational study with cross-sectional and longitudinal components. RESULTS: At recruitment, when patients were hyperthyroid and TRAb positive, Actinobacteria were significantly increased and Bacteroidetes significantly decreased in GD/GO compared with HCs. The Firmicutes to Bacteroidetes (F:B) ratio was significantly higher in GD/GO than in HCs. Differential abundance of 15 genera was observed in patients, being most skewed in mild GO. Bacteroides displayed positive and negative correlations with TSH and free thyroxine, respectively, and was also significantly associated with smoking in GO; smoking is a risk factor for GO but not GD. Longitudinal analyses revealed that the presence of certain bacteria (Clostridiales) at diagnosis correlated with the persistence of TRAb more than 200 days after commencing antithyroid drug treatment. CONCLUSION: The increased F:B ratio observed in GD/GO mirrors our finding in a murine model comparing TSHR-immunized with control mice. We defined a microbiome signature and identified changes associated with autoimmunity as distinct from those due to hyperthyroidism. Persistence of TRAb is predictive of relapse; identification of these patients at diagnosis, via their microbiome, could improve management with potential to eradicate Clostridiales.
引用
- Biscarini F, Masetti G, Muller I, et al. Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study. J Clin Endocrinol Metab. 2023. PMID: 36683389. doi:10.1210/clinem/dgad030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。